COX-2 and c-kit expression in canine gliomas

Veterinary and Comparative Oncology

Volumn 11, Issue 1, 2013, Pages 63-69

  Jankovsky, J M ^a   Newkirk, K M ^a   Ilha, M R ^b   Newman, S J ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

Astrocytoma; C kit; Canine; COX 2; Glioma; Oligodendroglioma

Indexed keywords

CYCLOOXYGENASE 2; STEM CELL FACTOR RECEPTOR;

ANIMAL; ANIMAL DISEASE; ARTICLE; BRAIN TUMOR; DOG; DOG DISEASE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY;

ANIMALS; BRAIN NEOPLASMS; CYCLOOXYGENASE 2; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; MALE; PROTO-ONCOGENE PROTEINS C-KIT; RETROSPECTIVE STUDIES;

CANIS FAMILIARIS;

EID: 84873748657     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2011.00302.x     Document Type: Article

References (42)

1. Snyder JM, Shofer FS, Van Winkle TJ and Massicotte C. Canine intracranial primary neoplasia: 173 cases (1986-2003). Journal of Veterinary Internal Medicine 2006; 20: 669-675.
2. Priester WA and Mantel N. Occurrence of tumors in domestic animals. Data from 12 United States and Canadian colleges of veterinary medicine. Journal of the National Cancer Institute 1971; 47: 1333-1344.
3. Koestner A, Bilzer T, Fatzer R, Schulman FY, Summers BA and Van Winkle TJ. Histological classification of tumors of the nervous system of domestic animals. In: World Health Organization International Histological Classification of Tumors of Domestic Animals, FY Shulman ed., Washington, DC, Armed Forces Institute of Pathology, American Registry of Pathology, 1999: 17-20.
4. Hayes HM, Priester WA and Pendergradd TW. Occurrence of nervous-tissue tumors in cattle, horses, cats and dogs. International Journal of Cancer 1975; 15: 39-47.
5. Stoica G, Levine J, Wolff J and Murphy K. Canine astrocytic tumors: a comparative review. Veterinary Pathology 2011; 48: 266-275.
6. Young BD, Levine JM, Porter BF, Chen-Allen AV, Rossmeisl JH, Platt SR, Kent M, Fosgate GT and Schatzberg SJ. Magnetic resonance imaging features of intracranial astrocytomas and oligodendrogliomas in dogs. Veterinary Radiology & Ultrasound 2011; 52: 132-141.
7. nd edn., Dewey CW, ed., Ames, IA, Blackwell Publishing, 2008: 158-168.
8. Dimski DS and Cook JR. Carmustine-induced partial remission of an astrocytoma in a dog. Journal of the American Animal Hospital Association 1990; 26: 179-182.
9. Central Brain Tumor Registry of the United States (CBTRUS) (2011). Statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2007 http://www.cbtrus.org [accessed 7 June 2011].
10. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA and Edwards BK. eds., SEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda, MD, 2011, http://seer.cancer.gov/csr/1975_2008/ [accessed 7 June 2011].
11. Hess KR, Broglio KR and Bondy ML. Adult glioma trends in the United States 1977-2000. Cancer 2004; 101: 2293-2299.
12. Ohgaki H and Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. Journal of Neuropathology and Experimental Neurology 2005; 64: 479-489.
13. Higgins RJ, Dickinson PJ, LeConteur RA, Bollen AW, Wang H, Wang H, Corely LJ, Moore LM, Zang W and Fuller GN. Spontaneous canine gliomas: overexpression of EGFR, PDGFRα and IGFBP2 demonstrated by tissue microarray immunophenotyping. Journal of Neurooncology 2010; 98: 49-55.
14. Lipsitz D, Higgins RJ, Kortz GD, Dickinson PJ, Bollen AW, Naydan DK and LeConteur RA. Glioblastoma multiforme: clinical findings, magnetic resonance imaging, and pathology in five dogs. Veterinary Pathology 2003; 40: 659-669.
15. Vandevelde M, Fankhauser R and Luginbuhl H. Immunocytochemical studies in canine neuroectodermal brain tumors. Acta Neuropathologica 1985; 66: 111-116.
16. Grosch S, Maier TJ, Schiffmann S and Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. Journal of the National Cancer Institute 2006; 98: 736-747.
17. Dore M, Lanthier I and Sirois J. Cyclooxygenase-2 expression in canine mammary tumors. Veterinary Pathology 2003; 40: 207-212.
18. McEntee MF, Cates JM and Neilsen N. Cyclooxygenase-2 expression in spontaneous intestinal neoplasia of dogs. Veterinary Pathology 2002; 39: 428-436.
19. Rossmeisl JH, Jr. Robertson JL, Zimmerman KL, Higgins MA and Geiger DA. Cyclooxygenase-2 (COX-2) expression in canine intracranial meningiomas. Veterinary and Comparative Oncology 2009; 7: 173-180.
20. Buccoliero AM, Caldarella A, Arganini L, Mennonna P, Gallina P, Taddei A and Taddei GL. Cyclooxygenase-2 in oligodendroglioma: possible prognostic significance. Neuropathology 2004; 24: 201-207.
21. Castilla EA, Prayson RA, Kanner AA, Rybicki LA, Tubbs RR, Vogelbaum MA and Barnett GH. Cyclooxygenase-2 in oligodendroglial neoplasms. Cancer 2003; 98: 1465-1472.
22. Deininger MH, Meyermann R, Trautmann K, Morgalla M, Duffner F, Grote EH, Wickboldt J and Schluesener HJ. Cyclooxygenase (COX)-1 expressing macrophages/microglial cells and COX-2 expressing astrocytes accumulate during oligodendroglioma progression. Brain Research 2000; 885: 111-116.
23. El-Sayed M and Taha MM. Immunohistochemical expression of cyclooxygenase-2 in astrocytoma: correlation with angiogenesis, tumor progression and survival. Turkish Neurosurgery 2011; 21: 27-35.
24. Hara A and Okayasu I. Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance. Acta Neuropathologica 2004; 108: 43-48.
25. Joki T, Heese O, Nikas DC, Bello L, Zhang J, Kraeft S, Seyfried NT, Abe T, Chen LB, Carroll RS and Black PM. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Research 2000; 60: 4926-4931.
26. Lee JM, Jung S, Rhu HH, Kim IY and Lee MC. Cyclooxygenase-2 expression predicts prognosis in astrocytic tumors. Journal of Korean Neurosurgical Society 2004; 36: 437-442.
27. Prayson RA, Castilla EA, Vogelbaum MA and Barnett GH. Cyclooxygenase-2 (COX-2) expression by immunohistochemistry in glioblastoma multiforme. Annals of Diagnostic Pathology 2002; 6: 148-153.
28. Shono T, Tofilon PJ, Bruner JM, Owolabi O and Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Research 2001; 61: 4375-4381.
29. Temel SG and Kahveci Z. Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroma and astrocytoma. Journal of Molecular Histology 2009; 40: 369-377.
30. Bijnsdorp IV, van den Berg J, Kuipers GK, Wedekind LE, Slotman BJ, van Rijn J, Lafleur MV and Sminia P. Radiosensitizing potential of the selective cyclooxygenase-2 (COX-2) inhibitor meloxicam on human glioma cells. Journal of Neurooncology 2007; 85: 25-31.
31. Heller DA, Fan TM, de Lorimer LP, Charney SC, Barger AM, Tannehill-Gregg SH, Rosol TJ and Wallig MA. In vitro cyclooxygenase-2 protein expression and enzymatic activity in neoplastic cells. Journal of Veterinary Internal Medicine 2007; 21: 1048-1055.
32. Kang KB, Wang TT, Woon CT, Cheah ES, Moore XL, Zhu C and Wong MC. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. International Journal of Radiation Oncology Biology Physics 2007; 67: 888-896.
33. Ma HI, Chiou SH, Hueng DY, Tai LK, Huang PI, Kao CL, Chen YW and Sytwu HK. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects; laboratory investigation. Journal of Neurosurgery 2011; 114: 651-662.
34. Van Nifterik KA, Van Den Berg J, Slotman BJ and Van Rijn J. Anti-tumor effects by a trimodal combination of temolozolomide, meloxicam and X-rays in cultures of human glioma cells. International Journal of Radiation Biology 2011; 87: 192-201.
35. Frost D, Lasota J and Miettinen M. Gastrointestinal stromal tumors and leiomyomas in the dog: a histopathologic, immunohistochemical, and molecular genetic study of 50 cases. Veterinary Pathology 2003; 40: 42-54.
36. Preziosi R, Morini M and Sarli G. Expression of the KIT protein (CD117) in primary cutaneous mast cell tumors of the dog. Journal of Veterinary Diagnostic Investigation 2004; 16: 554-561.
37. Cetin N, Dienel G and Gokden M. CD117 expression in glial tumors. Journal of Neurooncology 2005; 75: 195-202.
38. Dehghan A, Mahjoub H and Rajeipour A. Determination of CD117 expression in glial tumors and its comparison between high grade and low grade tumors. Iranian Journal of Pathology 2010; 5: 109-115.
39. Kristt DS, Reedy E and Yarden Y. Receptor tyrosine kinase expression in astrocytic lesions: similar features in gliosis and glioma. Neurosurgery 1993; 33: 106-115.
40. Morris PG and Abrey LE. Novel targeted agents for platelet-derived growth factor receptor and c-KIT in malignant gliomas. Targeted Oncology 2010; 5: 193-200.
41. Natali PG, Nicotra MR, Sures I, Santoro E, Bigotti A and Ullrich A. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Research 1992; 52: 6139-6143.
42. Sihto H, Tynninen O, Butzow R, Saarialho-Kere U and Joensuu H. Endothelial cell KIT expression in human tumours. Journal of Pathology 2007; 211: 481-488.